Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly affects patients' quality of life (QoL). Limited data exists on the effects AD poses on sexual well-being. Objective: To evaluate the impact of moderate-to-severe atopic dermatitis (MtS-AD) on sexual well-being and assess the efficacy of advanced therapies, specifically abrocitinib and dupilumab, in improving sexual health. Methods: In this retrospective study, medical records and responses to an 8-item questionnaire assessing sexual well-being in patients with MtS-AD were reviewed at baseline and after 52 weeks of treatment with abrocitinib or dupilumab. Results: In total, 44 patients were included (mean age: 30.8, 43.2% female). Before treatment, 88.6% reported AD affected their sexual well-being, including feeling unattractive (79.5%), avoiding sexual activity (68.2%), feeling ashamed or embarrassed (68.2%), and experiencing rejection (56.8%). After 52 weeks of treatment with abrocitinib or dupilumab, these negative perceptions and behaviors significantly reduced. Conclusions: MtS-AD negatively impacts patients' sexual well-being; however, advanced therapies like abrocitinib and dupilumab can significantly improve the sexual lives of affected patients, highlighting the broader benefits of these treatments on QoL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
